| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $102.9M | +28.5% |
| SG&A Expense | $29.8M | +23.8% |
| Operating Income | -$132.8M | -27.4% |
| Income Tax | $0 | — |
| Net Income | -$119.9M | -38.7% |
| EPS (Basic) | -$2.01 | -33.1% |
| EPS (Diluted) | -$2.01 | -33.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $77.4M | -15.9% |
| Current Assets | $265.4M | -23.6% |
| Total Assets | $282.6M | -22.3% |
| Current Liabilities | $18.1M | +24.0% |
| Total Liabilities | $23.4M | +14.8% |
| Stockholders' Equity | $259.2M | -24.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$95.1M | -36.4% |
| Capital Expenditures | $141K | -78.8% |
| Investing Cash Flow | $72.5M | +173.6% |
| Financing Cash Flow | $8.1M | -96.0% |
| Free Cash Flow | -$95.3M | -35.3% |